Safe and Healthy Schools

Sponsor
University of Wisconsin, Madison (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05105789
Collaborator
(none)
450
1
1
12.7
35.5

Study Details

Study Description

Brief Summary

This study will target Madison Metropolitan School District (MMSD) school children ages 4-19 and staff who have not had a previous positive COVID-19 test within the past 3 months. It will enroll children and adults for 1-3 days to explore whether serial "at-home" BinaxNOW testing is feasible and non-inferior to "at school" single PCR testing for the evaluation of symptomatic individuals with a negative initial BinaxNOW. It will also explore whether lollipop swabs are more acceptable and perform as well as nasal swabs with polymerase chain reaction (PCR) testing.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: BinaxNOW Test
  • Diagnostic Test: "Lollipop" swab
N/A

Detailed Description

Study Design: This is a quantitative community-based study, conducted in the K-12 setting with school children 4-19 years old, teachers, and staff.

If a participant's initial at-school BinaxNOW test is positive, then they will only complete the lollipop swab for PCR testing. They will NOT do the at-home BinaxNOW test.

If a participant's initial at-school BinaxNOW test is negative, then they will complete both the lollipop swab for PCR testing AND an at-home BinaxNOW test approximately 24 hours later.

If the participant is unwilling or unable to complete the at-home test, they will be presented with a lollipop swab only option.

Aim 1: The investigators will test the hypothesis that serial at-home BinaxNOW testing will be feasible and non-inferior to the single at-school PCR testing program. To do this, the investigators will distribute over-the-counter BinaxNOW antigen tests to volunteer families, and create a protocol to ensure families can perform and report test results accurately to the school.

Two key questions will be addressed:
  1. Is 'at-home' BinaxNOW testing feasible for families?

  2. Is serial 'at-home' BinaxNOW testing non-inferior to 'at-school' single PCR testing?

Aim 2: The investigators will test the hypothesis that lollipop swabs are more acceptable to individuals and PCR testing is non-inferior to performing PCR on nasal swabs. To test this hypothesis, the investigators will work with MMSD schools to incorporate a lollipop swab for PCR at the time a symptomatic student or staff receives a nasal swab for PCR that is part of the Department of Health Services (DHS) program.

Two key questions will be addressed:
  1. Are lollipop swabs more acceptable to individuals when compared to nasal swabs?

  2. Will lollipop swabs perform as well as nasal swabs with PCR-based testing?

Hypotheses to be tested:
  • Aim 1.1: "At-home" BinaxNOW testing will be feasible for families.

  • Aim 1.2: Serial "at-home" BinaxNOW testing is non-inferior to "at school" single PCR testing.

  • Aim 2.1: Lollipop swabs are more acceptable to individuals than nasal swabs.

  • Aim 2.2: Lollipop swabs will perform as well as nasal swabs with PCR-based testing.

Protocol Amendment 2/4/22 to expand the upper eligible age for children from 14 to 19 years and to recognize the potential supply chain limitations of BinaxNOW tests. If the study team does not have any BinaxNOW tests due to a supply shortage, the BinaxNOW procedures will be dropped and only the lollipop swab will be collected.

Protocol Amendment 5/16/22 extends the study timeline and adds a lollipop swab only option.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
450 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Safe and Healthy Schools
Actual Study Start Date :
Oct 11, 2021
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: BinaxNOW Test + Lollipop PCR

If a symptomatic participant's initial at-school BinaxNOW test was positive, then their study participation is complete after providing the lollipop swab for PCR testing. If a symptomatic participant's initial at-school BinaxNOW test was negative, then they will be asked to complete an at-home BinaxNOW test approximately 24 hours later. For the at-home BinaxNOW testing, the participant will schedule a follow-up virtual visit with the study coordinator. If they are unable to complete a virtual visit, they will schedule an in-person home visit. They will also be sent home with a BinaxNOW testing kit.

Diagnostic Test: BinaxNOW Test
diagnostic test for SARS-CoV-2
Other Names:
  • BinaxNOW COVID-19 Ag Card
  • Diagnostic Test: "Lollipop" swab
    A lollipop swab, is an oral swab to collect saliva, sucked on like a lollipop for 20 seconds.

    Outcome Measures

    Primary Outcome Measures

    1. Negative Predictive Value (NPV) of BinaxNOW [up to 2 days]

      The primary diagnostic outcome measure will be the negative predictive value (NPV). The NPV of BinaxNow is ~91% in symptomatic subjects. The null hypothesis is that the negative predictive value of BinaxNOW is at least 91% (which is the reported rate in symptomatic subjects after a single test) versus the alternative hypothesis that the NPV is greater than 91%.

    2. Tabulated Results from Nasal vs Lollipop Swab-based PCR tests [up to 1 day]

      The hypothesis is that the lollipop swab test will be non-inferior to the gold-standard PCR testing of nasal swabs. Concordance between the PCR test results will be evaluated by calculating the Kappa statistic which will be reported along with corresponding two-sided 95% confidence interval. The nonparametric bootstrap technique will be used to construct the confidence interval. A kappa statistic of >0.95 will be considered as sufficient to define lollipop swab test non-inferior to the gold standard PCR testing of nasal swabs.

    3. Number of successfully completed at-home tests [up to 24 hours]

      Feasibility of 'at-home' BinaxNOW testing will be determined by number of successfully completed at-home tests. At-home test taking will be monitored by study team remotely (via zoom or similar).

    4. Percent of participants who answer 'yes' when asked if lollipop swabs are more acceptable than nasal swabs [up to 1 day]

      To address the acceptability of lollipop swabs vs nasal swabs, the study team will ask participants a binary question: Are lollipop swabs more acceptable to participants when compared to nasal swabs? Yes/No.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    4 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • school children ages 4-19

    • MMSD staff

    • have at least one symptom of COVID-19

    • have not had a positive COVID-19 test in the past 3 months

    • will undergo nasal PCR testing at an MMSD elementary school

    Exclusion Criteria:
    • received a positive COVID-19 test in the past 3 months
    Criteria for inclusion in the final study sample:
    • Aim 1. Symptomatic participants with a negative at-school BinaxNOW test and nasal PCR results who complete both the lollipop PCR and at-home BinaxNOW tests within 72 hours will be included in the final study sample.

    • Aim 2. Symptomatic participants who provide a lollipop swab that is successfully resulted.

    Criteria for exclusion in the final study sample:
    • Aim 1

    • Missing nasal PCR result

    • Do not successfully complete an at-home BinaxNOW test within 72 hours of the at-school BinaxNOW test

    • Aim 2

    • Missing nasal PCR result

    • Missing lollipop PCR result

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Community Locations Madison Wisconsin United States 53705

    Sponsors and Collaborators

    • University of Wisconsin, Madison

    Investigators

    • Principal Investigator: Ellen R Wald, MD, University of Wisconsin, Madison

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Wisconsin, Madison
    ClinicalTrials.gov Identifier:
    NCT05105789
    Other Study ID Numbers:
    • 2021-0790
    • Protocol Version 5/8/22
    • A536756
    First Posted:
    Nov 3, 2021
    Last Update Posted:
    Aug 24, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by University of Wisconsin, Madison
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 24, 2022